Ascendiant Capital Markets Forecasts RenovoRx Q3 Earnings

RenovoRx, Inc. (NASDAQ:RNXT) – Analysts at Ascendiant Capital Markets decreased their Q3 2026 earnings estimates for shares of RenovoRx in a report issued on Sunday, May 31st. Ascendiant Capital Markets analyst E. Woo now expects that the company will earn ($0.07) per share for the quarter, down from their previous estimate of ($0.06). Ascendiant Capital Markets currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.30) per share. Ascendiant Capital Markets also issued estimates for RenovoRx’s FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.27) EPS.

RenovoRx (NASDAQ:RNXT) last issued its earnings results on Thursday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). RenovoRx had a negative net margin of 823.98% and a negative return on equity of 135.03%. The business had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $0.47 million.

A number of other brokerages have also recently weighed in on RNXT. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of RenovoRx in a research note on Wednesday, April 8th. Wall Street Zen cut shares of RenovoRx from a “hold” rating to a “strong sell” rating in a research note on Saturday, April 4th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

RenovoRx Price Performance

Shares of NASDAQ:RNXT opened at $0.91 on Thursday. The stock has a market cap of $40.84 million, a P/E ratio of -2.74 and a beta of 1.01. The firm has a fifty day moving average price of $0.93 and a 200 day moving average price of $0.93. RenovoRx has a 1-year low of $0.70 and a 1-year high of $1.45.

Institutional Trading of RenovoRx

A number of large investors have recently bought and sold shares of RNXT. XTX Topco Ltd boosted its stake in RenovoRx by 58.6% during the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock worth $42,000 after purchasing an additional 18,525 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of RenovoRx in the 2nd quarter worth $98,000. Citadel Advisors LLC acquired a new stake in shares of RenovoRx in the 3rd quarter worth $154,000. Wealthspire Advisors LLC acquired a new stake in shares of RenovoRx in the 4th quarter worth $212,000. Finally, Geode Capital Management LLC lifted its stake in shares of RenovoRx by 9.9% in the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after acquiring an additional 31,730 shares during the period. Institutional investors and hedge funds own 3.10% of the company’s stock.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.